×
About 31,225 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  9,719 results

Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vacc...
https://doi.org/10.1001/jamaoncol.2021.5942
JAMA Oncology; Terpos E, Rajkumar SV et. al.

Dec 3rd, 2021 - Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination.|2021|Terpos E,Rajkumar SV,Leung N,|

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04557098

Dec 3rd, 2021 - Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and ...
https://clinicaltrials.gov/ct2/show/NCT03652064

Dec 3rd, 2021 - This study will evaluate participants with newly diagnosed multiple myeloma (MM) for whom hematopoietic stem cell transplant is not planned as initial therapy. The data available from other available studies suggests that addition of daratumumab w...

see more →

Guidelines  33 results

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...

KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological mali...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.

Dec 6th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Pra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.

Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.
https://doi.org/10.1200/JCO.18.02096
Journal of Clinical Oncology : Official Journal of the Am... Mikhael J, Ismaila N et. al.

Apr 2nd, 2019 - To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to con...

see more →

Drugs  142 results see all →

Clinicaltrials.gov  759 results

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04557098

Dec 3rd, 2021 - Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
https://clinicaltrials.gov/ct2/show/NCT03768960

Dec 3rd, 2021 - The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome in...

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and ...
https://clinicaltrials.gov/ct2/show/NCT03652064

Dec 3rd, 2021 - This study will evaluate participants with newly diagnosed multiple myeloma (MM) for whom hematopoietic stem cell transplant is not planned as initial therapy. The data available from other available studies suggests that addition of daratumumab w...

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04634552

Dec 3rd, 2021 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT02086552

Dec 3rd, 2021 - PRIMARY OBJECTIVES: I. To assess the complete response (CR) rate with lenalidomide and sonidegib (LDE225) maintenance following an upfront single autologous stem cell transplant (SCT). SECONDARY OBJECTIVES: I. To assess the toxicity of lenalidomid...

see more →

News  1,818 results

Did Trump Have COVID at First Debate? Cats Busted for Misinfo; Myeloma Drug Yanked
https://www.medpagetoday.com/infectiousdisease/covid19/95968

Dec 2nd, 2021 - Note that some links may require registration or subscription. Donald Trump tested positive for COVID-19 days before the first presidential debate against Joe Biden, according to his chief of staff at the time and other former aids; Trump denounce...

Dr. Rosko on Disparities Within Clinical Trials in Multiple Myeloma
https://www.onclive.com/view/dr-rosko-on-disparities-within-clinical-trials-in-multiple-myeloma

Nov 23rd, 2021 - Ashley E. Rosko, MD, oncologist, associate professor, Department of Internal Medicine, The Ohio State University (OSU), medical director, Oncogeriatric Program, The OSU Comprehensive Cancer Center–James, discusses disparities within clinical trial...

Dr. Lee on Defining Smoldering Multiple Myeloma
https://www.onclive.com/view/dr-lee-on-defining-smoldering-multiple-myeloma

Nov 22nd, 2021 - Sarah S. Lee, MD, physician, Seattle Cancer Care Alliance, assistant professor, Division of Medical Oncology, University of Washington School of Medicine, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discus...

Mortality Rate Associated With COVID-19 Breakthrough Cases Remains High in Hematologic Malignancies
https://www.onclive.com/view/mortality-rate-associated-with-covid-19-breakthrough-cases-remains-high-in-hematologic-malignancies

Nov 18th, 2021 - Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available, according to preliminary dat...

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium

Nov 15th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...

see more →

Patient Education  19 results see all →